1. Catalent will increase its production of Moderna’s COVID-19 vaccine to about 400 vials a minute at its plant in Bloomington, Ind.
2. The FDA said April 1 it will allow Moderna to include up to 15 doses per vial of its COVID-19 vaccine, up from 10 doses.
3. HHS directed Johnson & Johnson to oversee COVID-19 vaccine manufacturing at a Maryland Emergent BioSolutions plant after 15 million doses were ruined there because of an ingredient mix-up.
4. Johnson & Johnson began administering its COVID-19 vaccine to 12-17-year-old participants of its ongoing phase 2a clinical trial, the drugmaker said April 5.
5. For Pfizer’s COVID-19 vaccine, the immune response after one dose among people who have previously had the disease was similar to the immune response recorded after two doses among people who have not had the disease, according to research published April 1 in Nature.
6. Pfizer said April 1 that data from a recent phase 3 trial showed its COVID-19 vaccine is effective against the B.1.351 coronavirus variant first detected in South Africa and offers protection for at least six months.
More articles on surgery centers:
Will Biden, Congress be friendly to ASCs and physician ownership?
7 ASC moves in Arizona
Tips to power profitability in surgery centers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.